# A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

> **NCT04869592** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 3100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- **BIOLOGICAL:** high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT04869592
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-25
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 3100 (ACTUAL)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869592, "A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04869592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*